Online inquiry

IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ73MR)

This product GTTS-WQ73MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets H1-0 gene. The antibody can be applied in Glioblastoma multiforme (GBM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_005318.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3005
UniProt ID P07305
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ73MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4619MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ4350MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIW-8405
GTTS-WQ6980MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ETI-204
GTTS-WQ1760MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADCT-301
GTTS-WQ13976MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ7391MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ10557MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ5832MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ChAglyCD
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW